EDU - EDU ME and ASTS among pre market gainers

Day One Biopharmaceuticals (DAWN) +81% announces positive initial data from pivotal FIREFLY-1 trial of Tovorafenib (DAY101) in relapsed pediatric low-grade Glioma. Redbox Entertainment (RDBX) +30%. Ekso Bionics Holdings (EKSO) +22% receives FDA clearance to market its EksoNR Robotic Exoskeleton for use with multiple sclerosis patients. LENSAR (LNSR) +16% receives U.S. FDA clearance of ALLY adaptive cataract treatment system. Gracell Biotechnologies Inc. (GRCL) +11%. New Oriental Education & Technology (EDU) +11%. AST SpaceMobile (ASTS) +6% announces summer launch date of BlueWalker 3 for direct-to-Cell phone connectivity testing. OptiNose (OPTN) +8% announces positive top-line results of ReOpen2, its second phase 3 clinical trial of XHANCE for treatment of chronic sinusitis. Homology Medicines (FIXX) +7% announces FDA lifted clinical hold on pheNIX gene therapy trial for PKU. 23andMe Holding (ME) +6%.

For further details see:

EDU, ME and ASTS among pre market gainers